CN116407578A - 一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方 - Google Patents
一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方 Download PDFInfo
- Publication number
- CN116407578A CN116407578A CN202310456836.1A CN202310456836A CN116407578A CN 116407578 A CN116407578 A CN 116407578A CN 202310456836 A CN202310456836 A CN 202310456836A CN 116407578 A CN116407578 A CN 116407578A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- insomnia
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims abstract description 49
- 206010022437 insomnia Diseases 0.000 title claims abstract description 49
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 33
- 208000013403 hyperactivity Diseases 0.000 title claims abstract description 20
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 14
- 241000237502 Ostreidae Species 0.000 claims abstract description 13
- 235000020636 oyster Nutrition 0.000 claims abstract description 13
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 10
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940116229 borneol Drugs 0.000 claims abstract description 10
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 10
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 9
- 235000005412 red sage Nutrition 0.000 claims abstract description 9
- 241001521901 Tribulus lanuginosus Species 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 4
- 235000021419 vinegar Nutrition 0.000 claims abstract description 4
- 239000000052 vinegar Substances 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 84
- 238000001467 acupuncture Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 208000002173 dizziness Diseases 0.000 abstract description 19
- 210000002216 heart Anatomy 0.000 abstract description 14
- 210000004185 liver Anatomy 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 12
- 206010019233 Headaches Diseases 0.000 abstract description 5
- 231100000869 headache Toxicity 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 4
- 238000010926 purge Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 231100000862 numbness Toxicity 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 30
- 230000035488 systolic blood pressure Effects 0.000 description 23
- 208000011580 syndromic disease Diseases 0.000 description 21
- 230000035487 diastolic blood pressure Effects 0.000 description 20
- 230000003860 sleep quality Effects 0.000 description 13
- 230000036772 blood pressure Effects 0.000 description 11
- 230000001976 improved effect Effects 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000000044 Amnesia Diseases 0.000 description 6
- 208000031091 Amnestic disease Diseases 0.000 description 6
- 206010033557 Palpitations Diseases 0.000 description 6
- 230000006986 amnesia Effects 0.000 description 6
- 230000010354 integration Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940127088 antihypertensive drug Drugs 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- LTUJKAYZIMMJEP-UHFFFAOYSA-N 9-[4-(4-carbazol-9-yl-2-methylphenyl)-3-methylphenyl]carbazole Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1C1=CC=C(C=2C(=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C)C(C)=C1 LTUJKAYZIMMJEP-UHFFFAOYSA-N 0.000 description 2
- 102100024736 ATP-dependent RNA helicase DDX19B Human genes 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 101100285704 Arabidopsis thaliana HSBP gene Proteins 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 2
- 101100116287 Homo sapiens DDX19B gene Proteins 0.000 description 2
- 101000746142 Homo sapiens RNA polymerase-associated protein CTR9 homolog Proteins 0.000 description 2
- 101000759808 Homo sapiens Testis-expressed basic protein 1 Proteins 0.000 description 2
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102100023292 Testis-expressed basic protein 1 Human genes 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- PQYJRMFWJJONBO-UHFFFAOYSA-N Tris(2,3-dibromopropyl) phosphate Chemical compound BrCC(Br)COP(=O)(OCC(Br)CBr)OCC(Br)CBr PQYJRMFWJJONBO-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000026843 stiff neck Diseases 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于临床辅助治疗心肝火旺型高血压并失眠病的一种中药敷贴配方及制备方法。本发明的技术方案为:取龙骨30份,牡蛎30份,丹参10份,白蒺藜10份,冰片6份研磨成细粉,加醋调和成糊状。即为高血压并病失眠的中药敷贴。本发明通过中药敷贴心俞穴和神门穴,泻心肝之毒火、滋心肝之阴,达到缓解高血压引起的头晕头痛、肢体麻木,以及失眠的目的。本方用药合理,所制成的中药毒副作用小,配合中医经典配穴法纳支法使用有效率更高。
Description
技术领域
本发明涉及中药治疗高血压病、失眠的技术领域,更具体的说是一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方。
背景技术
高血压病是以体循环动脉压升高为特点,可伴有心、脑、肾等多脏器受损的综合征。患者血压升高时可出现头晕、头痛、颈项部僵硬等多种症状。临床研究进一步发现高血压病患者中,心肝火旺型高血压(以下简称为高血压)的特点是:头晕、面目红赤、脾气暴躁、口干舌燥、口苦、头晕、舌苔增厚、眼干、睡眠不稳定、妇女月经紊乱,故常常并发失眠,文献报到认为可能是与高血压导致大脑皮层兴奋-抑制功能失调有关。而长期失眠可使得交感神经过度兴奋,血压进一步升高,周而复始形成恶性循环,严重影响患者的生活质量、加速患者心脑血管事件的发生。
在临床治疗方面,西药虽然降压起效迅速,但却无法有效缓解患者头晕、头痛、失眠等临床症状,存在一定的局限性。目前临床针对高血压并失眠病的西医治疗方案,主要采用降压药联合非苯二氮卓类治疗失眠药物为主。而此类抗失眠药物容易出现口苦和头晕等不良反应,严重者会影响其中枢神经系统和消化系统,出现瞌睡、乏力、恶心、呕吐等症状。同时此类药物长期应用安全性还不确定,但目前尚没有安全可靠的药物替代。传统的中医治疗主要以口服中药水煎剂或复方制剂为主,虽然可有效缓解头晕、失眠等症状,且毒副作用较小,但多数性味强烈,部分患者难以耐受性,长期治疗依从性较差。
中药敷贴法起源于中医经络学说。该学说认为人体的经络循行路线是疾病证候的发生和反映的关键部位,每条经脉和其所属脏腑发生病变时,经络就会通过它所联系的有关部位或器官,反映出症状和体征。因此,激发特定穴位的经气、疏通瘀阻的经络,可达到调整人体气血、平衡脏腑阴阳功能的治疗目的。在临床使用中,由于穴位贴敷疗法是一种无创无痛的穴位疗法,更易被患者所接受,加之其作用直接、疗效确切、便于推广,可用于口服中药的替代治疗。
发明内容
针对目前治疗高血压并失眠病中的不足之处,本发明提供了一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方及其制法。本发明的目的是提供一组治疗心肝火旺型高血压并失眠病的中药配穴以及敷贴方法。为实现上述目的,本发明的技术方案如下:
一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方,按重量如下分组成:
龙骨10-40份,牡蛎10-40份,丹参5-20份,白蒺藜5-20份,冰片3-10份;
进一步,龙骨30份,牡蛎30份,丹参10份,白蒺藜10份,冰片6份。
在本发明中,该方通过将龙骨30份,牡蛎30份,丹参10份,白蒺藜10份,冰片6份研磨成细粉状,加适量醋调和成糊状。使用时将含有本发明中药组合物的无菌辅料贴于穴位处即可。
从中医学角度分析,心肝火旺型高血压并失眠病患者多为本虚标实,即心肝阴气亏虚、阳火过度亢盛为主。肝性刚烈,其气常有余,而其阴常有不足,故易化热生火伤阴,致阴不制阳、肝阳上亢。肝木之火有余常上扰心神,进一步加催心火旺盛、心阴亏虚,心肝火旺日久易导致心神不安,严重者易出现失眠、健忘等症。
本发明的有益效果是:本方以龙骨为君药,龙骨入手足少阴、厥阴经,性甘平,具有平肝益阴,潜敛浮阳,镇惊安神,敛汗固精之功。主治怔忡健忘,失眠多梦,自汗盗汗,遗精。牡蛎为臣药,归肝胆经,味咸、微寒。具有重镇安神,潜阳补阴之功。用于治疗惊悸失眠,眩晕耳鸣等证。龙骨得地阴而长,牡蛎得水液而生,两药皆具养阴之功、潜阳之力,龙骨牡蛎两者相伍,龙骨益阴而能潜上越之浮阳,牡蛎益阴而能摄下陷之沉阳,使阴液得补,阳气得潜,心神得安。张锡纯云:“龙骨入肝以安魂,牡蛎入肺以定魂。”丹参归心、肝经,性味苦、微寒,有活血通经,清心除烦之功。多用于治疗心烦不眠、心绞痛等证。白蒺藜入足厥阴肝经,性温、微苦,具有清肝明目之效。冰片入心经,性温、苦,具有通诸窍,散郁火,明目止痛之功。方中运用冰片芳香走窜,因其可“率领群药开结行滞,直达病所,拔病外出。”本发明使用时须循“纳支法”依次于11点至13点敷贴神门穴、15点至17点敷贴心俞穴。“纳支法”是古代针灸配穴经典名方《子午流注法》的一个分支,是根据十二小时经气流行顺序辨经施治的一种特殊穴位治疗方法。本法指出午时(11点至13点)气血注与手少阴心经,有利于周身血液循环;申时(15点至17点)膀胱经旺,有利于泻掉周身“火气”。而神门穴属于手少阴心经的穴位之一,位于腕部,腕掌侧横纹尺侧端,尺侧腕屈肌腱的桡侧凹陷处,本穴主治心烦,惊悸,怔仲,健忘,失眠,胸胁痛等疾病。心俞属足太阳膀胱经,在背部,当第5胸椎棘突下,旁开1.5寸,主治失眠,惊悸,健忘,心烦,心律不齐,心绞痛等疾病。根据心肝火旺型高血压并失眠病病机特点,循此法刺激少阴心经、太阳膀胱经的特定穴位,可起到疏肝泻火、定心安神之功,对治疗本病有着事半功倍的效果。
附图说明
图1表示治疗前两组患者对比,其中:T开头代表治疗组,C开头代表对照组;a表示中医证候积分对照;b表示收缩压对照;c表示舒张压对照;d表示PSQI评分对照;P>0.05。
图2表示对照组治疗前后组内患者对比,其中:Q开头代表治疗前,H开头代表治疗后;a表示中医证候积分对照;b表示收缩压对照;c表示舒张压对照;d表示PSQI评分对照;★:P<0.05;★★:P<0.01。
图3表示治疗组治疗前后组内患者对比,注:Q:治疗前,H:治疗后;a:中医证候积分;b:收缩压;c:舒张压;d:PSQI评分;★:P<0.05;★★:P<0.01。
图4治疗后两组患者对比,注:T:治疗组;C:对照组,a:中医证候积分;b:收缩压;c:舒张压;d:PSQI评分;★:P<0.05;★★:P<0.01。
图5匹兹堡睡眠质量指数量表。
实施例
一般资料:
研究对象:2022年9月至2023年3月,选取在江苏省中西医结合医院(即申请人江苏省中医药研究院的附属临床医院)心血管科住院高血压并失眠病患者30例。纳入标准:诊断符合《中国高血压防治指南(2018年修订版)》有关高血压的诊断标准,高血压定义为:在未使用降压药物的情况下,非同日3次测量诊室血压,SBP≥140mmHg和(或)DBP≥90mmHg,即西医诊断为原发性高血压,中医诊断为心肝火旺型高血压分型;同时符合《中国成人失眠诊断与治疗指南》有关失眠的诊断标准,即主要表现为入睡困难、睡眠浅、多梦易醒等症状;年龄30~85岁;签署知情同意者。随机分为治疗组和对照组,每组均为20例,两组患者年龄、性别、基础疾病无明显统计学差异(P>0.05)。
方法:
1.药物成分:龙骨30份,牡蛎30份,丹参10份,白蒺藜10份,冰片6份。
2.处理方法:具体取龙骨30g,牡蛎30g,丹参10g,白蒺藜10g,冰片6g研磨成细粉状,加醋调和成糊状。使用时将含有本物的无菌辅料,敷贴神门穴的时间为11点至13点、敷贴心俞穴的时间为15点至17点。
3.观察指标:1.治疗前后两组血压水平,包括收缩压和舒张压;2.睡眠质量:参照1989年由Buyss提出的临床评定失眠的常用量表,匹兹堡睡眠质量指数(Pittsburgh sleepquality index,PSQI),如图5所示,记录治疗前后PSQI的总分;3.参照《中药新药临床研究指导原则》对眩晕头痛、心悸失眠、口干口苦、五心烦热、耳鸣健忘中医症状进行量化评分(根据严重程度分为无、轻、中、重4级,对应分值为0、2、4、6分),治疗后证候总积分减少≥70%为显效;治疗后证候总积分减少≥30%但<70%为有效;眩晕头痛、心悸失眠等症状无明显改善者,甚至症状加重者,证候积分减少<30%为无效。
结果
1.基线分布(年龄、性别)
对照组与治疗组患者年龄、性别无统计学差异。(P>0.05)
表1两组病人一般情况
组别 | 年龄 | 男(性别) | 女(性别) |
对照组 | 67.60±12.39 | 6 | 9 |
治疗组 | 64.53±15.94 | 8 | 7 |
2治疗前后情况
治疗前治疗组与对照组中医证候积分、血压、PSQI比较
表2两组患者治疗前观察指标
详见图1,治疗前两组患者对比,其中TZJF表示治疗组的中医证候积分,CZJF表示对照组的中医证候积分;TSBP表示治疗组的收缩压,CSBP表示对照组的收缩压;TDBP表示治疗组的舒张压,CDBP表示对照组的舒张压;TPSQI表示治疗组的匹兹堡睡眠质量指数,CPSQ[表示对照组的匹兹堡睡眠质量指数。
治疗前,两组患者的年龄、性别及中医证候积分、血压、PSQI评分之间无显著差异(P>0.05),说明两组患者具有可比性。堡睡眠质量指数。
治疗前,两组患者的年龄、性别及中医证候积分、血压、PSQI评分之间无显著差异(P>0.05),说明两组患者具有可比性。
3.1对照组治疗前后组内中医证候积分、血压、PSQI评分比较
详见图2,治疗组治疗前后组内患者对比。注:Q:治疗前,H:治疗后;a:中医证候积分;b:收缩压;c:舒张压;d:PSQI评分;★:P<0.05;★★:P<0.01,具体地说其中QZJF表示治疗前的中医证候积分,HZJF表示治疗后的中医证候积分;QSBP表示治疗前的收缩压,HSBP表示治疗后的收缩压;QDBP表示治疗前的舒张压,HDBP表示治疗后的舒张压;QPSQI表示治疗前的匹兹堡睡眠质量指数,HPSQI表示治疗后的匹兹堡睡眠质量指数。
治疗后,治疗组的中医证候积分、收缩压、舒张压、PSQI评分较治疗前显著改善(P<0.01)。
3.2治疗组干预前后组内中医证候积分、血压、PSQI评分比较
详见图3,注:Q:治疗前,H:治疗后;a:中医证候积分;b:收缩压;c:舒张压;d:PSQI评分;★:P<0.05;★★:P<0.01,具体地说其中QZJF表示治疗前的中医证候积分,HZJF表示治疗后的中医证候积分;QSBP表示治疗前的收缩压,HSBP表示治疗后的收缩压;QDBP表示治疗前的舒张压,HDBP表示治疗后的舒张压;QPSQI表示治疗前的匹兹堡睡眠质量指数,HPSQI表示治疗后的匹兹堡睡眠质量指数。
治疗后,治疗组的中医证候积分、收缩压、舒张压、PSQI评分较治疗前显著改善(P<0.01)。
3.3治疗后治疗组与对照组中医证候积分、血压、PSQI评分比较
表3两组患者治疗后观察指标
详见图4,治疗后两组患者对比。
注:T:治疗组;C:对照组,a:中医证候积分;b:收缩压;c:舒张压;d:PSQI评分;★:p<0.05;★★:P<0.01,具体其中TZJF表示治疗组的中医证候积分,CZJF表示对照组的中医证候积分;TSBP表示治疗组的收缩压,CSBP表示对照组的收缩压;TDBP表示治疗组的舒张压,CDBP表示对照组的舒张压;TPSQI表示治疗组的匹兹堡睡眠质量指数,CPSQI表示对照组的匹兹堡睡眠质量指数。
治疗后,中药治疗组的中医证候积分、PSQI评分较对照组显著改善(P<0.01);两组治疗后收缩压、舒张压无显著差异(P>0.05)。
3.4两组患者中医证候临床疗效总体比较
根据两组患者的中医证候积分评定临床疗效等级,并运用卡方检验来进行比较,最终发现治疗组的中医证候临床疗效明显优于对照组(P<0.05),详见表4。
表4两组患者中医证候临床疗效
典型病例
病例一:王某,男,65岁。初诊日期:2022年12月23日。主诉:反复头晕伴失眠1年余,加重1月。患者近1年来反复发作头晕不适伴失眠,自测血压偏高。后患者长期服用降压药物治疗,但头晕症状仍时有发作,且失眠情况无法改善。近一月来患者因情绪激动后出现头晕伴行走不稳,失眠较前进一步加重,出现入睡困难、睡眠时间偏短仅2-3小时、睡眠不深、醒来后无法再次入睡等情况。随着失眠无法改善,患者日间更出现精神恍惚,烦躁易怒、健忘等症状。符合心肝火旺型高血压的病机特点,由于患者拒绝服用安眠药物,遂循“纳支法”依次敷贴患者神门、心俞二穴,治疗两周后患者头晕症状明显减轻,且失眠症状得到改善。目前患者每晚睡眠时间可达4-6小时。随访至今患者病情仍在逐渐好转。
病例二:徐某,女,71岁。初诊日期:2023年1月15日。主诉:头晕伴失眠1月余。患者高血压病史数年,近来出现头晕伴失眠症状。主要表现为日间头晕症状隐隐且持续存在、注意力不集中、健忘、情绪易激惹,夜间出现入睡困难、睡眠时间片段、醒后难以再次入睡等情况,符合心肝火旺型高血压的病机特点。由于患者拒绝服用安眠镇静类药物,遂予中药贴敷神门、心俞二穴。治疗数周后患者失眠症状明显改善,日间头晕症状逐渐消失。患者目前仍在门诊定期进行中药贴敷治疗,随访至今病情稳定。
结论
根据临床观察我们发现,治疗组的中医证候积分、收缩压、舒张压、PSQI评分较治疗前显著改善(P<0.01)。相较于对照组,治疗组干预后的中医证候积分、PSQI评分改善更为明显(P<0.01),但治疗组平均收缩压虽较对照组更低,但两者无显著差异(P>0.05)。因此,综合上述临床观察结果可以证实,本发明具有辅助治疗心肝火旺型高血压并失眠病的良好临床效果。
Claims (5)
1.一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方,其特征在于,按如下重量份组成:龙骨10-40份,牡蛎10-40份,丹参5-20份,白蒺藜5-20份,冰片3-10份。
2.如权利要求1所述的一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方,其特征在于,具体重量份为:龙骨30份,牡蛎30份,丹参10份,白蒺藜10份,冰片6份。
3.如权利要求1或2所述的一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方,其特征在于,将前述组份研磨成细粉状、加醋调和成糊状,将含有前述混合物的无菌辅料敷贴于穴位。
4.如权利要求3所述的一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方,其特征在于,所述穴位为神门穴、心俞穴。
5.如权利要求4所述的一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方,其特征在于,敷贴神门穴的时间为每日11点至13点、敷贴心俞穴的时间为每日15点至17点。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310456836.1A CN116407578B (zh) | 2023-04-17 | 2023-04-17 | 一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310456836.1A CN116407578B (zh) | 2023-04-17 | 2023-04-17 | 一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116407578A true CN116407578A (zh) | 2023-07-11 |
CN116407578B CN116407578B (zh) | 2024-04-05 |
Family
ID=87054489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310456836.1A Active CN116407578B (zh) | 2023-04-17 | 2023-04-17 | 一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116407578B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1555864A (zh) * | 2004-01-10 | 2004-12-22 | 郭士全 | 一种治疗高血压的药 |
CN111249355A (zh) * | 2020-03-24 | 2020-06-09 | 上海中医药大学附属岳阳中西医结合医院 | 一种预防和/或治疗失眠的中药穴位敷贴及其应用 |
CN115501304A (zh) * | 2022-10-09 | 2022-12-23 | 江苏省中医院 | 一种治疗心肝火旺型失眠症的中药复方组合物及其制备方法与应用 |
-
2023
- 2023-04-17 CN CN202310456836.1A patent/CN116407578B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1555864A (zh) * | 2004-01-10 | 2004-12-22 | 郭士全 | 一种治疗高血压的药 |
CN111249355A (zh) * | 2020-03-24 | 2020-06-09 | 上海中医药大学附属岳阳中西医结合医院 | 一种预防和/或治疗失眠的中药穴位敷贴及其应用 |
CN115501304A (zh) * | 2022-10-09 | 2022-12-23 | 江苏省中医院 | 一种治疗心肝火旺型失眠症的中药复方组合物及其制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
李晓东: "从肝论治失眠症临床分析", 光明中医, vol. 30, no. 12, pages 2609 - 2610 * |
Also Published As
Publication number | Publication date |
---|---|
CN116407578B (zh) | 2024-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112826900B (zh) | 一种治疗脂溢性脱发的中药组合物及其药物制剂 | |
CN116407578B (zh) | 一种辅助治疗心肝火旺型高血压并失眠病的中药敷贴配方 | |
CN112675281A (zh) | 一种用于治疗抑郁症和失眠症的泡脚汤 | |
CN103859865B (zh) | 一种用于治疗失眠的保健床垫 | |
CN114288235B (zh) | 一种艾灸用中药组合物及其制备方法和应用 | |
CN103920102B (zh) | 一种治疗原发性低血压的中药药物 | |
Jing et al. | Intradermal needle at auricular acupoint for insomnia: A randomized controlled trial | |
CN104757841A (zh) | 一种中药保健枕及其制备方法 | |
CN100998660B (zh) | 治疗椎动脉型颈椎病中药贴及其制备方法 | |
RU2703137C1 (ru) | Способ комплексной коррекции коморбидной патологии у пациенток в перименопаузе | |
Liu | Clinical observations of mind-regulating acupuncture in treating 100 cases of peripheral facial paralysis | |
CN108686178B (zh) | 一种治疗帕金森病的中药穴位贴膏剂及其制备方法 | |
CN112773862B (zh) | 一种中药组合物及其制备方法和应用 | |
CN111643606B (zh) | 一种用以治疗失眠的凝胶贴膏及其制备方法 | |
CN109512874B (zh) | 一种小儿外感发热用推拿按摩乳剂及其制备方法 | |
Jin-rong | Treatment on 76 Cases of Insomnia by Electro-Acupuncture and Psychological Counseling. | |
Zhang et al. | Clinical Observation of Twenty-Two Cases of Herpes Zoster in Pregnancy Treated by Cotton-Spreading Moxibustion and Half-Needling Method Therapy. | |
CN116712479A (zh) | 一种辅助治疗冠状动脉供血不足痰瘀互结证的中药组合物 | |
Tu et al. | 22. Efficacy of auricular acupressure using semen vaccariae (Wang Bu Liu Xing) seeds on acupoints of nada protocol in treating primary insomnia: A pilot study | |
Ojha et al. | AYURVEDA APPROACH AND EFFECT OF JALOKAVACHARANA IN THE MANAGEMENT OF INDRALUPTA A CASE STUDY | |
Mahajan et al. | Chapter-5 Shiroabhitapa: A Persisting Ailment | |
Sumarni et al. | EFFECTIVENESS OF LAVENDER AROMATHERAPY INHALATION ON HEMODIALYSIS SIDE EFFECTS IN PATIENTS WITH CHRONIC RENAL FAILURE | |
Tukmachi | Acupuncture therapy in diseases failing to respond to Western medicine | |
CN118403102A (zh) | 一种穴位按摩助眠复方精油及其制备方法 | |
CN113069524A (zh) | 一种祛风湿通经络的药酒及药酒的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |